Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with...
Main Authors: | Christina Darden, Mark Price, David Ray, Grace Goldstein, Diana Goss, Lee Bennett, Diana Garbinsky, Ramya Thota |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-09-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-021-00355-5 |
Similar Items
-
Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
by: Ortendahl JD, et al.
Published: (2017-08-01) -
Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
by: Roberto eBaldelli
Published: (2014-02-01) -
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
by: Yuheng Hu, et al.
Published: (2021-05-01) -
Somatostatin Analogs in Clinical Practice: A Review
by: Mariana Gomes-Porras, et al.
Published: (2020-02-01) -
Small Intestinal Neuroendocrine Tumor Analyses : Somatostatin Analog Effects and MicroRNA Profiling
by: Li, Su-Chen
Published: (2014)